INVESTIGADORES
ISLAN German Abel
artículos
Título:
Development and characterization of new enzymatic modified hybrid CaCO3 microparticles to obtain nano-architectured surfaces for enhanced drug loading
Autor/es:
ISLAN GA; CACICEDO ML; BOSIO VE; CASTRO GR
Revista:
JOURNAL OF COLLOID AND INTERFACE SCIENCE
Editorial:
ACADEMIC PRESS INC ELSEVIER SCIENCE
Referencias:
Lugar: Amsterdam; Año: 2015 vol. 439 p. 76 - 87
ISSN:
0021-9797
Resumen:
Hypothesis Biopolymer-CaCO3 hybrid microparticles exposed to hydrolytic enzymes can provide new surface tailorable architectures. Soluble Alginate lyase hydrolyzed alginate chains exposed on microparticle surface are generating considerable matrix changes. The change of porosity and surface to volume ratio is expected to influence absorption of drugs, thereby affecting controlled release profiles. The developed hybrid system potentially shows interesting properties for lung drug administration. Experimental Hybrid microparticles were developed by colloidal co-precipitation of CaCO3 in presence of biopolymers: alginate (Alg) or Alg-High Methoxylated Pectin (HMP), followed by treatment with Alginate Lyase (AL). Surface architectures were observed by SEM. The increase in area to volume ratio was confirmed by BET isotherms. Also, enzymatic changes were elucidated by biophysical methods (EDAX, DSC, FTIR, XRD) and determination of the total carbohydrates content. Levofloxacin (a fluoroquinolone antibiotic) as model drug was incorporated by absorption. The drug release profile and the antimicrobial activity of the microparticles were tested against Pseudomonas aeruginosa. Findings After enzyme treatment, microspheres showed 4 μm diameter and increased porosity. While CaCO3-Alg microspheres resulted in a rougher surface, CaCO3-Alg-HMP ones exhibited ?nano-balloon? patterns on surface. Both AL-treated microparticles showed up to 3 and 7 times higher levofloxacin encapsulation than no treated ones. Microparticles showed controlled drug release profiles and enhanced antimicrobial effect. The present work demonstrates a significant progress in the development of new carriers with potential application for lung infections treatment.